CN110951764A - 一种表达荧光素酶的产酸克雷伯菌及其用途 - Google Patents
一种表达荧光素酶的产酸克雷伯菌及其用途 Download PDFInfo
- Publication number
- CN110951764A CN110951764A CN201911258813.XA CN201911258813A CN110951764A CN 110951764 A CN110951764 A CN 110951764A CN 201911258813 A CN201911258813 A CN 201911258813A CN 110951764 A CN110951764 A CN 110951764A
- Authority
- CN
- China
- Prior art keywords
- klebsiella oxytoca
- lux
- plasmid
- pbbr1
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000588749 Klebsiella oxytoca Species 0.000 title claims abstract description 63
- 108060001084 Luciferase Proteins 0.000 title claims abstract description 23
- 239000005089 Luciferase Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000013612 plasmid Substances 0.000 claims abstract description 49
- 230000001954 sterilising effect Effects 0.000 claims abstract description 35
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 26
- 238000012216 screening Methods 0.000 claims abstract description 16
- 238000010276 construction Methods 0.000 claims abstract description 7
- 101150097493 D gene Proteins 0.000 claims description 19
- 101150013191 E gene Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 238000010171 animal model Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000645 desinfectant Substances 0.000 claims description 5
- 238000007877 drug screening Methods 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 108091008053 gene clusters Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 9
- 229940088710 antibiotic agent Drugs 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000009466 transformation Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000013112 stability test Methods 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000000137 annealing Methods 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 206010011409 Cross infection Diseases 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101150096873 LUX gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000534000 Berula erecta Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/22—Testing for sterility conditions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明利用质粒构建和电转化技术,构建了含有荧光素酶基因簇(luciferase gene cassette,lux)的产酸克雷伯菌,经自发荧光鉴定及菌株的传代稳定性试验与培养特性的观察,最终获得了可稳定表达荧光素酶的产酸克雷伯菌(KOX‑LUX)。为研究产酸克雷伯菌相关疾病进展,筛选合适的杀菌方法、抗生素等提供重要的可视化研究工具。
Description
技术领域
本发明涉及微生物医药领域,具体涉及一种含有荧光素酶基因的泛宿主质粒和稳定表达荧光素酶的产酸克雷伯菌的构建方法,该方法构建获得的菌株,以及该菌株在筛选杀菌方法或者筛选药物以及制备感染动物模型等方面的用途。
背景技术
产酸克雷伯菌(Klebsiella oxytoca,KOX)是社区和医院感染常见的革兰氏阴性细菌,其表面的荚膜多糖是其主要的毒力因子。产酸克雷伯菌能够表达广谱β-内酰胺酶(extended spectrumβ-lactamases,ESBL)和碳青霉烯酶,因此能产生β-内酰胺和碳青霉烯类抗生素耐药,已成为临床治疗的难题,因此,亟需有力工具评估现行抗生素使用的疗效、适合的药物,例如抗生素或其他杀菌方法的效果。
生物发光是生物体内在酶的作用下发光的现象。生物发光现象广泛存在细菌、昆虫等生物体中。利用萤光素酶基因(luciferas gene cassette,LUX)基因标记细胞的生物发光技术具有操作简便、结果直观、不依赖底物、对机体损伤小等优点。该技术已广泛应用于肿瘤生长监测和转移示踪、基因治疗、目标基因表达的检测等多个领域。
近年来研究表明,产酸克雷伯菌属于外科术后常见的感染细菌之一,但是对于该菌感染防控研究并未深入。传统制作克雷伯菌属感受态采用化学方法,制作过程繁琐且感受态效率不稳定。
发明内容
本发明将萤光素酶基因LUX A/B/C/D/E连接至质粒,构建包含LUX A/B/C/D/E基因簇的质粒,并将通过电转化至产酸克雷伯菌,经过传代,筛选可稳定表达荧光素酶的产酸克雷伯菌,并将其用于筛选合适的杀菌方法或者筛选药物以及制备感染动物模型等方面。因此,
本发明提供一种质粒,所述质粒包括荧光素酶基因簇LUX A/B/C/D/E。
优选的,所述质粒为泛宿主质粒,该质粒可以在大肠杆菌中完成构建过程,其启动子能够被产酸克雷伯菌在内的多种革兰氏阴性杆菌识别。
本发明还提供一种产酸克雷伯菌(KOX-LUX),所述产酸克雷伯菌能稳定表达荧光素酶。
本发明还提供一种上述产酸克雷伯菌的构建方法,所述构建方法包括:
(1)制备包含LUX A/B/C/D/E基因簇的质粒;优选的,所述质粒为泛宿主质粒,更优选的,所述质粒为泛宿主质粒pBBR1。
(2)制备电转化感受态产酸克雷伯菌;
(3)将步骤(1)获得的包含LUX A/B/C/D/E基因簇的质粒电转化感受态产酸克雷伯菌,挑选阳性菌落。
优选的,所述步骤(1)包括:(a)将LUX A/B/C/D/E基因簇克隆至泛宿主质粒;(b)将质粒电转化至大肠杆菌感受态细胞;(c)筛选阳性大肠杆菌;(d)从阳性大肠杆菌中提取包含LUX A/B/C/D/E基因簇的泛宿主质粒。
进一步,所述步骤(a)包括①、LUXA/B/C/D/E基因簇扩增;②、pBBR1MCS-1双酶切;③、将步骤②的酶切片段胶回收后与步骤①扩增的LUXA/B/C/D/E基因簇使用Gibson连接方法连接获得环状质粒。
更进一步,步骤①LUX A/B/C/D/E基因簇扩增时采用高保真酶,其退火温度低于推荐温度2-4℃。
本发明还提供一种上述产酸克雷伯菌在筛选杀菌方法中的应用。
本发明还提供一种上述产酸克雷伯菌在筛选药物中的应用。
本发明还提供一种上述产酸克雷伯菌在制备动物模型中的应用。
优选的,所述动物模型可以是造烧伤模型、手术模型、感染模型等。
本发明还提供一种杀菌方法的评估方法,所述评估方法包括利用上述产酸克雷伯菌对杀菌方法进行评估。
本发明还提供一种药物筛选方法,所述药物筛选方法包括利用上述产酸克雷伯菌对药物,例如抗生素进行筛选,以寻找对产酸克雷伯菌的敏感、有效的抗生素。
所述评估方法可以是体内或者体外的评估方法。所述评估方法不是治疗方法。该评估方法用来评估候选杀菌方法,对候选杀菌方法的杀菌效果进行检测和比较,以确定哪些杀菌方法可以作为杀灭产酸克雷伯菌,哪些不能,或者,比较不同杀菌方法的杀菌程度,即杀菌效果不是必然的,只是一种可能性。
所述药物筛选方法可以是体内或者体外的筛选方法。所述药物筛选方法不是治疗方法。该方法用来筛选药物,对候选药物的药效进行检测和比较,以确定哪些候选药物可以作为药物,哪些不能作为药物,或者,比较不同药物的药效敏感程度,即治疗效果不是必然的,只是一种可能性。
本发明还提供一种动物模型的制备方法,所述制备方法包括将上述产酸克雷伯菌注入动物体内。优选的,所述动物模型可以是造烧伤模型、手术模型、感染模型等。所述体内注入方式可以是鼻饲、灌胃、腹腔注射、尾静脉注射等。
优选的,所述菌株在动物体内富集浓度不低于105Cfu/mL。
本发明还提供一种产酸克雷伯菌的杀菌方法,所述杀菌方法包括利用紫外照射或者84消毒液对携带产酸克雷伯菌的物品进行杀菌。
优选的,所述携带产酸克雷伯菌的物品包括医疗器械,医疗材料等医疗物品,例如手术床,手术器械,医用床,医用床单等等,或者携带产酸克雷伯菌的食品或土壤等等。
优选的,所述杀菌方法包括紫外照射30min以上,或者以10%的84消毒液对物品进行消毒。
本发明的良好技术效果包括:
1、本发明使用电转化方法制备感受态细胞,操作简便易得,而且转化效率高,转化后细菌稳定表达荧光素酶概率为60%。优选的,LUX A/B/C/D/E基因簇扩增时采用高保真酶,其退火温度低于推荐温度2-3℃时,扩增效率最高。使用Gibson连接方法,提高连接效率。
2、首次利用电转化方法将泛宿主质粒将荧光素酶转化至产酸克雷伯菌,从而获得生物发光的产酸克雷伯菌,方便的观察产酸克雷伯菌的各种性能,包括生长,体内分布等各种性能;
3、利用本发明表达萤光素酶的产酸克雷伯菌可以便捷,快速、直观的筛选合适的药物,例如各种抗生素,为患者快速找到合适的抗生素可以使患者早日康复。
4、利用本发明表达萤光素酶的产酸克雷伯菌筛选到适合的杀菌方法,如实施例所示的紫外线和84消毒液都可以有效的杀灭携带产酸克雷伯菌的物品,可以有效的对医疗物品进行杀菌,防止院内感染;
5、可视化观察不同的理化措施对于KOX的杀菌效果,对临床合理进行环境杀菌,为采取接触预防、患者隔离、环境清洁等更多干预措施提供依据,对于预防控制院内感染具有重要的意义;
6、可视化追踪KOX在实验动物体内的分布情况,对于优化抗菌药物使用方案,具有重要的指导意义。
以上只是概括了本发明的一些方面,不是也不应该认为是在任何方面限制本发明。本说明书提到的所有专利和出版物都是通过参考文献作为整体而引入本发明的。本领域的技术人员应认识到,对本发明可作某些改变并不偏离本发明的构思或范围。下面的实施例进一步详细说明本发明,不能认为是限制本发明或本发明所说明的具体方法的范围。
附图说明
图1:pBBR1-LUX A/B/C/D/E质粒构建策略图,其中A为pBBR1-LUX A/B/C/D/E质粒构建示意图,上:PCR线性扩增LUX A/B/C/D/E基因基团,下:KpnI/HindIII对pBBR1质粒进行双酶切。B为pBBR1-LUX A/B/C/D/E质粒转化到大肠杆菌示意图。
图2:PBBR1-LUX A/B/C/D/E质粒在大肠杆菌荧光素酶功能验证,其中(A)图中,DH5a-pBBR1为仅转化质粒pBBR1的对照组大肠杆菌,DH5a/pBBR1-LUX A/B/C/D/E为转化了pBBR1-LUX A/B/C/D/E的实验组大肠杆菌,(B)图为DH5a/pBBR1-LUX A/B/C/D/E在小动物活体成像仪上的结果。
图3:pBBR1-LUX A/B/C/D/E质粒在产酸克雷伯菌荧光素酶功能验证,其中(A)图中,KOX-D1/pBBR1为仅转化质粒pBBR1的对照组产酸克雷伯菌,KOX-D1/pBBR1-LUX A/B/C/D/E为转化了pBBR1-LUX A/B/C/D/E的实验组产酸克雷伯菌,(B)图为KOX-D1/pBBR1-LUX A/B/C/D/E在小动物活体成像仪上的结果。
图4:不同传代菌株的荧光强度,P3-P10依次表示第三代——第十代。
图5:不同浓度KOX–D1/pBBR1-LUX A/B/C/D/E的Luminescence荧光强度。
图6:不同理化杀菌方法对KOX–D1/pBBR1-LUX A/B/C/D/E的杀菌效果
具体实施方式
下面通过实施例对本发明进行详细说明,以使本发明的特征和优点更清楚。但应该指出,实施例用于理解本发明的构思,本发明的范围并不仅仅局限于本文中所列出的实施例。
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
1、试验材料:
大肠杆菌(Escherichia coli,E.coli)DH5a感受态细胞、质粒小提试剂盒购于天根生化科技有限公司。胶回收试剂盒购于德国QIAGEN公司。高保真DNA聚合酶Q5、高保真DNA连接酶、KpnI、HindIII限制性内切酶均购于美国NEB公司。pBAV1k-T5-LUX和pBBR1MCS-1购于淼灵质粒平台,氯霉素购自美国Thermo公司。
2、检测仪器:
Veritas微孔板光度计(Turner BioSystems)、NanoDropTM One超微量紫外分光光度计(Thermo)、IVIS Lumina LT小动物活体成像仪(珀金埃尔默)。
3、产酸克雷伯菌收集与准备
产酸克雷伯菌(KOX-D1)为我院住院患者分离。产酸克雷伯菌经全自动微生物分析仪(美国BD)进行细菌鉴定和药敏试验,鉴定为氯霉素敏感的产酸克雷伯菌(药敏结果的判断参照美国临床实验室标准化研究所的推荐标准)。
4、统计学分析:
利用GraphPad Prism 7.0软件进行统计分析,采用Kolmogorov-Simrnov对荧光值数据进行正态性检验。E.coli-pBBR1-lux和KOX-pBBR1-lux荧光信号检测数据为偏态分布,荧光值用中位数表示,两组间采用Wilcoxon秩和检验。不同浓度KOX-pBBR1-lux荧光信号检测数据为偏态分布,荧光值用均值表示,采用OneWay anova检验。以P<0.05为差异有统计学意义。
实施例1含有荧光素酶基因的泛宿主质粒的构建
1.LUXA/B/C/D/E基因簇扩增:
(1)、设计LUX基因簇的引物对
引物中的小写加粗序列为该序列与pBBR1的互补序列。
pBAV1k-T5-LUX质粒长度10546bp,其lux A/B/C/D/E基因簇受T5启动子操纵,共5663bp,我们采用使用Q5高保真DNA聚合酶和含有LUX基因簇的引物对,引物设计过程中加入与pBBR1相同的序列(图1A所示),扩增pBAV1k-T5-LUX质粒的LUX A/B/C/D/E基团。
(2)、LUX A/B/C/D/E基因簇PCR扩增
表1:LUX A/B/C/D/E基因簇扩增PCR反应体系
配置好上述反应体系后进行PCR反应,PCR程序设置如表2:
表2:PCR程序设置
程序进行至4℃时,取出反应产物,关闭PCR仪后进行后续PCR产物鉴定。
同时,申请人发现,依据高保真DNA聚合酶网站推荐的退火温度(61℃),获得DNA片段的效果并不好。经梯度PCR实验,其退火温度低于推荐温度2-4℃时(即57-59℃),扩增效率最高,确定使用58℃退火。
(3)、琼脂糖凝胶电泳:
1)配制适当浓度(1.5%)琼脂糖凝胶:称取1.5g琼脂糖(Gene Star)称重后溶至100ml TAE中,微波炉加热至琼脂糖完全溶解,溶液澄清透明。冷却40-50℃,加入10μl核酸染料(Gene star)。混匀后倾倒至组装好的胶槽内,室温静置30分钟。
2)组装电泳装置后上样:胶孔中加入DNA Ladder(Gene Star)及PCR产物(如有需要,加入0.66μl 10×loading buffer)各6μl,恒压120V电泳10分钟。紫外凝胶成像仪下观查PCR条带是否阳性,并将阳性条带位置与DNA Ladder比对,条带分子量与目标DNA(5000bp左右)一致,鉴定为阳性。
(4)、PCR产物测序并分析:
PCR产物凝胶回收:收集正确大小的DNA:用洁净刀片在紫外灯下切取目的DNA片段后称重,将切取的凝胶收集至1.5ml离心管。利用DNA凝胶回收与纯化试剂盒。按100μg凝胶加入300μl溶胶缓冲液,50℃震荡孵育,观察胶完全融化后加入异丙醇(每100μg凝胶加入100μl异丙醇)。将600μl上述液体转移至离心柱内,12000rpm离心1分钟,弃套管内废液,再将离心柱插入套管内,若液体有剩余,则将剩余液体加入同一离心柱内重复此步骤。离心柱内加500μl清洗液,12000rpm离心1分钟,弃套管内废液。小心取出离心柱,插入新的离心管,12000rpm离心1分钟后打开盖子,室温静置两分钟去除残留的异丙醇H2O。将离心柱置入一个新的1.5ml离心管内,并加入50μl无核酸酶水,室温放置2分钟后12000rpm离心1分钟,收集回收的DNA。将回收的DNA标记后送往测序公司(华大基因)进行一代测序。测序结果与pBAV1k-T5-LUX质粒进行对比分析,测序结果表明扩增的片段为LUX基因基团,进行后续实验。
2.pBBR1MCS-1双酶切:
pBBR1是大小为4707bp的革兰氏阴性菌泛宿主质粒,该质粒带有氯霉素耐药基因(Chloramphenicol resistance gene,cmR)、pBBR1复制起始位点(pBBR1ori)、pBBR1(pBBR1rep)调节因子。该质粒的3321/3281bp处具有HindIII和KpnI限制性内切酶的单一酶切位点,采用HindIII/KpnI酶切的方法获得线性化的PBBR1质粒。其示意图如图1.A所示。pBBR1MCS-1质粒HindIII/KpnI酶切体系如表3所示。
表3:pBBR1MCS-1质粒HindIII/KpnI酶切体系
3.将上述酶切片段胶回收后与扩增的LUXA/B/C/D/E基因簇使用Gibson连接方法连接:
将上述两个线性化片段经鉴定和凝胶回收后,使用2×NEBuilder HiFi DNAAssembly连接酶连接,连接成功的环状质粒产物命名为pBBR1-lux,示意图如图1.B。pBBR1MCS-1HindIII/KpnI酶切位点连接LUXA/B/C/D/E基因簇体系如表4:
表4:pBBR1MCS-1HindIII/KpnI酶切位点连接LUXA/B/C/D/E基因簇体系(20μl)
4.产物转化至大肠杆菌感受态细胞:
连接后产物电转化至大肠杆菌DH5a感受态细胞,阳性细菌筛选后,扩增细菌,提取质粒并进行一代测序鉴定,鉴定测序正确后的质粒命名为pBBR1-LUX A/B/C/D/E(pBBR1-lux)。含有pBBR1-LUX A/B/C/D/E的大肠杆菌收集并保存至-70℃冰箱。
5.DH5a-pBBR1-LUX A/B/C/D/E表达荧光素酶功能验证
挑取转化pBBR1-lux A/B/C/D/E质粒的大肠杆菌阳性单菌落于含有氯霉素的LB液体培养基,37℃培养4小时后鉴定荧光值。阳性菌株传至第三代后,使用Veritas微孔板光度计检测其生物发光值(Luminesence),选取第三代仍具有Luminesence的菌落命名为DH5a/pBBR1-LUX A/B/C/D/E(DH5a/pBBR1-lux),使用IVIS Lumina LT小动物活体成像仪检测结果显示,DH5a/pBBR1-LUX A/B/C/D/E具有成像仪上具有可见荧光,如图2B,并且如图2A所示,DH5a/pBBR1-LUX A/B/C/D/E荧光值高达15000,和对照组DH5a-pBBR1仅为68相比,具有显著性的差异。
实施例2含有荧光素酶的产酸克雷伯菌荧光素基因表达的检测
1.产酸克雷伯菌电转化感受态制备
挑取产酸克雷伯菌单个菌落接种于液体BHI培养基,37℃静置培养过夜。取过夜培养的产酸克雷伯菌菌液以1:10的比例接种于新鲜的BHI培养基中,37℃静置培养至OD600=0.3~0.4。取出对数期菌液,冰浴30min后,4℃,4000rcf离心收集菌体,菌体分别用预冷的无菌双蒸水和预冷的1%蔗糖溶液洗涤两后,即为产酸克雷伯菌感受态细胞。
2.pBBR1-LUX A/B/C/D/E质粒电转化:
取5μl pBBR1-LUX A/B/C/D/E质粒加入到100μl产酸克雷伯菌感受态细胞中,混匀后冰浴10分钟。将上述混合物转移至预冷的0.1cm电击杯(美国伯乐)中,在电场强度:22.5kV/mm;电阻:200Ω;电容:25μF进行电转化。电击结束后,立即向电击杯中加入950μl,37℃预热的BH I培养基,于37℃静置培养1h后涂布于含25μg/ml氯霉素的哥伦比亚血平板培养基。37℃培养24h,挑取阳性菌落进行鉴定。
阳性菌落经过三代培养后,使用Veritas微孔板光度计检测其Luminesence值,选取具有Luminesence信号的菌落命名为KOX-D1/pBBR1-LUX A/B/C/D/E(KOX-D1/pBBR1-lux),使用IVIS Lumina LT小动物活体成像仪检测结果显示,KOX-D1/pBBR1-LUX A/B/C/D/E具有成像仪上具有可见荧光,如图3B所示。
如图3A所示,KOX-D1/pBBR1-LUX A/B/C/D/E荧光值高达400000,和对照组KOX-D1/pBBR1仅为128相比,具有显著性的差异。同时,也显著性的高于DH5a/pBBR1-LUX A/B/C/D/E的荧光值。
阳性菌落冻存于-70℃。一个月后划平板复苏得到的单菌落为第三代菌株(P3),将P3经1:1000稀释后培养至对数期(OD600=0.5-0.8)所得菌株为第四代菌株(P4)。依此类推得到P5、P6、P7、P8、P9、P10菌株。将上述菌株稀释至106cfu/ml,检测其荧光强度,其结果如图4所示,本发明的菌落可以稳定传代,到第十代,其荧光值依然可以保持在10000/107Cfu左右。
实施例3:不同浓度KOX-D1/pBBR1-LUX A/B/C/D/E荧光素酶强度检测
挑取KOX-D1/pBBR1-LUX A/B/C/D/E单菌落菌株,37℃培养4小时后,使用NanoDropTM One超微量紫外分光光度计检测细菌OD值。依据1OD=109菌落形成单位(colony-forming unit,Cfu)计算细菌浓度。将所得菌株按照1:10稀释6个梯度,在酶标仪上检测Luminesence值,结果如图5所示,Luminesence值随菌落浓度降低而降低,当菌株浓度为106Cfu和105Cfu时,其荧光强度分别为5869±215.9和660.2±215.9,低于105Cfu时,其荧光在小动物成像仪中不能被检测到,因此,建议该细菌用于动物实验时,所述菌株在动物体内富集浓度不能低于105Cfu/mL。
实施例4:不同处理方式对KOX-D1/pBBR1-LUX A/B/C/D/E杀菌效果的验证
我们采用了六种不同物理化学方法处理。物理方法:用接种环(1μl)对KOX-D1/pBBR1-LUX A/B/C/D/E进行三区划线,37℃敷箱中培养2h,紫外照射30min。化学方法:使用酒精(75%)、84消毒液(10%)、H2O2(30%)、NaOH(0.4%、4%)分别浸泡细菌接种环(1ul)30min,分别挑取1μl KOX-D1/pBBR1-LUX A/B/C/D/E进行三区划线。上述处理后的KOX–D1/pBBR1-LUX A/B/C/D/E平板37℃培养8h后,使用小动物成像仪观察KOX–D1/pBBR1-LUX A/B/C/D/E荧光值。
结果显示,紫外灯和84消毒液杀菌效果最强,能够完全杀菌:平板上未见KOX-D1/pBBR1-LUX A/B/C/D/E。酒精、H2O2和NaOH(0.4%,4%)有一定杀菌能力,但不能够完全杀灭KOX-D1/pBBR1-LUX A/B/C/D/E(不完全杀菌:平板上可见KOX-D1/pBBR1-LUX A/B/C/D/E,如图6所示)。
实施例5:KOX-D1/pBBR1-LUX A/B/C/D/E用于筛选抗生素
我们设计了不同抗生素杀菌方案。首先模拟感染环境的酸碱度、氧气含量,是否含有细胞因子等,可以模拟痰液、血液、尿液、粪便等环境。检测不同的抗生素浓度在特定的对于该菌的杀菌作用。优选不同抗生素使用浓度。
对于多重耐药菌,我们依据临床上的耐药菌治疗方案,优选特定条件下联合使用抗生素时不同的抗生素比例。
实施例6:KOX-D1/pBBR1-LUX A/B/C/D/E用于制备感染动物模型
将KOX-D1/pBBR1-LUX A/B/C/D/E稀释成2*109/ml。通过灌胃和腹腔注射方式感染C57小鼠(雌性,6-8周龄)。在小动物成像仪上观察细菌播散路径或定植位置。
以上详细描述了本发明的优选实施方式,但是,本发明并不限于上述实施方式中的具体细节,在本发明的技术构思范围内,可以对本发明的技术方案进行多种简单变型,这些简单变型均属于本发明的保护范围。
另外需要说明的是,在上述具体实施方式中所描述的各个具体技术特征,在不矛盾的情况下,可以通过任何合适的方式进行组合,为了避免不必要的重复,本发明对各种可能的组合方式不再另行说明。
此外,本发明的各种不同的实施方式之间也可以进行任意组合,只要其不违背本发明的思想,其同样应当视为本发明所公开的内容。
序列表
<110> 首都医科大学附属北京地坛医院
<120> 一种表达荧光素酶的产酸克雷伯菌及其用途
<130> 1
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 42
<212> DNA
<213> 人工序列()
<400> 1
agggaacaaa agctgggtac gattcaattg tgagcggata ac 42
<210> 2
<211> 40
<212> DNA
<213> 人工序列()
<400> 2
gctgcaggaa ttcgatatca atttgtccta ctcaggagag 40
Claims (10)
1.一种质粒,其特征在于,所述质粒包括荧光素酶基因簇LUX A/B/C/D/E。
2.一种产酸克雷伯菌,其特征在于,所述产酸克雷伯菌能稳定表达荧光素酶。
3.一种产酸克雷伯菌的构建方法,其特征在于,所述构建方法包括:
(1)制备包含LUX A/B/C/D/E基因簇的质粒;
(2)制备电转化感受态产酸克雷伯菌;
(3)将步骤(1)获得的包含LUX A/B/C/D/E基因簇的质粒电转化感受态产酸克雷伯菌,挑选阳性菌落。
4.如权利要求3所述构建方法,其特征在于,所述质粒为泛宿主质粒。
5.一种权利要求2所述产酸克雷伯菌的应用,其特征在于,所述应用包括在筛选杀菌方法中的应用,在筛选药物中的应用,或者,在制备动物模型中的应用。
6.一种杀菌方法的评估方法,其特征在于,所述评估方法包括利用权利要求2所述产酸克雷伯菌对杀菌方法进行评估。
7.一种药物筛选方法,其特征在于,所述药物筛选方法包括利用权利要求2所述产酸克雷伯菌对药物进行筛选。
8.一种动物模型的制备方法,其特征在于,所述制备方法包括将权利要求2所述产酸克雷伯菌注入动物体内。
9.一种产酸克雷伯菌的杀菌方法,其特征在于,所述杀菌方法包括利用紫外照射或者84消毒液对携带产酸克雷伯菌的物品进行杀菌。
10.如权利要求9所述的杀菌方法,其特征在于,所述杀菌方法包括紫外照射30min以上,或者以10%的84消毒液对物品进行消毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911258813.XA CN110951764A (zh) | 2019-12-10 | 2019-12-10 | 一种表达荧光素酶的产酸克雷伯菌及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911258813.XA CN110951764A (zh) | 2019-12-10 | 2019-12-10 | 一种表达荧光素酶的产酸克雷伯菌及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110951764A true CN110951764A (zh) | 2020-04-03 |
Family
ID=69980657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911258813.XA Pending CN110951764A (zh) | 2019-12-10 | 2019-12-10 | 一种表达荧光素酶的产酸克雷伯菌及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110951764A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112481182A (zh) * | 2020-12-07 | 2021-03-12 | 首都医科大学附属北京地坛医院 | 一种表达荧光素酶的vre及其用途 |
EP3988652A1 (en) * | 2020-10-23 | 2022-04-27 | Aden Hygiene, Ent. | Biological indicator for rapid verification of disinfection or sterilization |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0168933A2 (en) * | 1984-06-05 | 1986-01-22 | AMERSHAM INTERNATIONAL plc | Detection and/or identification of microorganisms in a test sample using bioluminescence or other exogenous genetically-introduced marker |
CN110066820A (zh) * | 2019-04-29 | 2019-07-30 | 华南农业大学 | 一种荧光菌株E.coli C600及构建方法与应用 |
-
2019
- 2019-12-10 CN CN201911258813.XA patent/CN110951764A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0168933A2 (en) * | 1984-06-05 | 1986-01-22 | AMERSHAM INTERNATIONAL plc | Detection and/or identification of microorganisms in a test sample using bioluminescence or other exogenous genetically-introduced marker |
CN110066820A (zh) * | 2019-04-29 | 2019-07-30 | 华南农业大学 | 一种荧光菌株E.coli C600及构建方法与应用 |
Non-Patent Citations (6)
Title |
---|
ABD-EL-HALEEM ET AL: "Detection of Nitrate/Nitrite Bioavailability in Wastewater Using a luxCDABEBased Klebsiella oxytoca Bioluminescent Bioreporter", 《JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY》 * |
ANTON V. BRYKSIN ET AL: "Rational Design of a Plasmid Origin That Replicates Efficiently in Both Gram-Positive and Gram-Negative Bacteria", 《PLOS ONE》 * |
XIWEN WANG ET AL: "Baterial Luciferase Gene Cassete as a Real-time Bioreporter for Infection Model and Drug Evaluation", 《CURRENT PHARMACEUTICAL DESIGN》 * |
张曙光 等: "《微生物学》", 31 August 2006 * |
蔡宝立 等: "《质粒分子生物学与实验方法》", 31 October 1999 * |
袁嘉丽 等: "《微生物学与免疫学》", 31 July 2017, 中国中医药出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3988652A1 (en) * | 2020-10-23 | 2022-04-27 | Aden Hygiene, Ent. | Biological indicator for rapid verification of disinfection or sterilization |
CN114480558A (zh) * | 2020-10-23 | 2022-05-13 | 亚丁卫生耳鼻喉科 | 用于快速验证消毒或灭菌的生物指示剂 |
CN112481182A (zh) * | 2020-12-07 | 2021-03-12 | 首都医科大学附属北京地坛医院 | 一种表达荧光素酶的vre及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Glenn et al. | Analysis of antimicrobial resistance genes detected in multidrug-resistant Salmonella enterica serovar Typhimurium isolated from food animals | |
CN113249499B (zh) | 一种伤寒沙门氏菌的检测试剂盒、其制备方法及其应用 | |
CN112725480B (zh) | 一种利用lamp技术快速检测伤寒沙门氏菌的引物组、检测方法、试剂盒 | |
KR20130087118A (ko) | 그람 음성균에 대해 세포 사멸능을 갖는 포도비리대 박테리오파지 | |
CN110951764A (zh) | 一种表达荧光素酶的产酸克雷伯菌及其用途 | |
CN110168097A (zh) | 基于通过单荧光膜染色和流动细胞分析的独特光谱强度比分析的快速抗微生物敏感性测试方法 | |
CN111607550A (zh) | 一种表达荧光素酶的高产酒克雷伯菌及其用途 | |
CN108728559A (zh) | 检测大肠埃希氏菌o157的rpa引物、探针、试剂盒和方法 | |
CN113150086B (zh) | 幽门螺杆菌HefC重组蛋白及其应用 | |
CN110964684A (zh) | 表达荧光素酶的产碳青霉烯酶肺炎克雷伯菌及其用途 | |
US20130029863A1 (en) | Method for detecting microorganisms | |
CN110656192B (zh) | 一种检测脑膜炎奈瑟氏菌的环介导等温扩增引物组及检测方法 | |
Shaaban et al. | Evaluation of a new antimicrobial agent production (RSMM C3) by using metagenomics approaches from Egyptian marine biota | |
CN114480690A (zh) | 金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌核酸快速检测方法及试剂盒 | |
Ziyi et al. | Biological characteristics and genomic information of a bacteriophage against pan-drug resistant Klebsiella pneumoniae in a burn patient and its effects on bacterial biofilm | |
CN108342499B (zh) | 一对同时快速检测无乳链球菌和海豚链球菌的引物及其应用 | |
CN112481182A (zh) | 一种表达荧光素酶的vre及其用途 | |
İnci et al. | Fine-needle aspiration as a diagnostic tool for recurrent tonsillitis | |
Hanoon et al. | Molecular detection of Pseudomonas Aeruginosa isolated from chicken cans in the markets of Al-Muthanna Province | |
CN111304347A (zh) | 一种在养殖现场快速检测轮虫弧菌的pcr反应体系 | |
JP4261366B2 (ja) | 食物を毒する細菌を検出するためのプライマー及びその使用 | |
CN110184368B (zh) | 一种检测towneri不动杆菌的特异性引物及方法和应用 | |
CN110184371B (zh) | 一种检测皮特不动杆菌的特异性引物及其方法和应用 | |
CN110184370B (zh) | 一种检测约翰逊不动杆菌特异性引物及方法和应用 | |
Po et al. | Characterization of Protein Domain Function via in vitro DNA Shuffling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200403 |